AstraZeneca (LON:AZN)‘s stock had its “hold” rating reiterated by stock analysts at Jefferies Financial Group in a research note issued on Thursday, ThisIsMoney.Co.Uk reports.
A number of other equities research analysts have also weighed in on AZN. HSBC boosted their price objective on AstraZeneca from GBX 6,450 ($79.37) to GBX 6,690 ($82.33) and gave the stock a “reduce” rating in a research report on Thursday, April 30th. JPMorgan Chase & Co. set a GBX 9,500 ($116.91) price objective on AstraZeneca and gave the stock a “buy” rating in a research report on Wednesday. UBS Group set a GBX 7,300 ($89.84) price objective on AstraZeneca and gave the stock a “sell” rating in a research report on Wednesday, June 10th. Bryan, Garnier & Co boosted their price objective on AstraZeneca from GBX 8,780 ($108.05) to GBX 9,100 ($111.99) and gave the stock a “buy” rating in a research report on Tuesday, June 2nd. Finally, Credit Suisse Group restated an “outperform” rating on shares of AstraZeneca in a research report on Tuesday, June 9th. Six investment analysts have rated the stock with a sell rating, two have assigned a hold rating and twelve have given a buy rating to the company’s stock. AstraZeneca has a consensus rating of “Hold” and an average target price of GBX 8,308.89 ($102.25).
AstraZeneca stock opened at GBX 8,505 ($104.66) on Thursday. The company has a debt-to-equity ratio of 171.72, a quick ratio of 0.56 and a current ratio of 0.75. AstraZeneca has a 52 week low of GBX 5,871 ($72.25) and a 52 week high of GBX 9,537.09 ($117.37). The stock has a market capitalization of $111.28 billion and a P/E ratio of 73.29. The stock has a fifty day moving average of GBX 8,515.84 and a 200-day moving average of GBX 7,825.20.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Further Reading: What member countries make up the G-20?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.